Annals of Oncology Advance Access published online on November 9, 2005
Annals of Oncology, doi:10.1093/annonc/mdj032
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 HSK, Dr Horst Schmidt Klinik, Department of Gynecology & Gynecologic Oncology, Wiesbaden, Germany
* To whom correspondence should be addressed. Background: Single-agent platinum and single-agent pegylated liposomal doxorubicin (PLD) are both effective in the treatment of gynecologic malignancies. Based on evidence that combination platinum-containing regimens offer superior efficacy versus single-agent regimens, we conducted this study to determine the maximum tolerated dose (MTD) of PLD in combination with carboplatin. Patients and methods: In this phase I/II dose-finding study, six courses of PLD (20, 30, 40 or 50 mg/m2) and carboplatin (AUC 6) were administered every 28 days to women with advanced gynecologic malignancies. Three to six patients were treated at each dose level; an additional 12 patients were treated at the MTD. Results: PLD 40 mg/m2 was identified as the MTD when administered with carboplatin. Five of 18 patients experienced a dose-limiting toxicity at the MTD; two patients had grade 3/4 neutropenia, and one each had grade 3 emesis and grade 3 thrombocytopenia and thrombosis. No patient developed cardiotoxicity. In 11 patients evaluable for response, there were two complete responses, two partial responses and four patients with stable disease. Conclusions: The MTD for PLD when administered in combination with carboplatin is 40 mg/m2. This regimen is well tolerated and offers promising activity in women with advanced gynecologic malignancies.
Received August 18, 2005
Revised August 23, 2005
Accepted September 5, 2005
original article
Pegylated liposomal doxorubicin and carboplatin in advanced gynecologic tumors: a prospective phase I/II study of the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR)
2 University of Muenchen-Grosshadern, Department of Gynecology & Obstetrics, Muenchen, Germany
3 Evangelisches Krankenhaus Duesseldorf, Department of Gynecology & Obstetrics, Duesseldorf, Germany
4 University of Schleswig-Holstein, Campus Kiel, Department of Gynecology & Obstetrics, Kiel, Germany
5 Technical University Muenchen, Department of Gynecologiy & Obstetrics, Muenchen, Germany
6 University of Dresden, Department of Gynecology & Obstetrics, Dresden, Germany
7 University of Muenster, Department of Gynecology & Obstetrics, Muenster, Germany
8 St-Vincentius-Hospital, Department of Gynecology & Obstetrics, Karlsruhe, Germany
9 University of Essen, Department of Gynecologic & Obstetrics, Essen, Germany
10 AGO-OVAR, Central Study Office, Wiesbaden, Germany
A. du Bois, E-mail: dubois.hsk-wiesbaden{at}uumail.de
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. Humber, J. Tierney, R. Symonds, M Collingwood, J Kirwan, C Williams, and J. Green Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration Ann. Onc., March 1, 2007; 18(3): 409 - 420. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J-M Ferrero, B Weber, J-F Geay, D Lepille, H Orfeuvre, M Combe, F Mayer, B Leduc, H Bourgeois, D Paraiso, et al. Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial Ann. Onc., February 1, 2007; 18(2): 263 - 268. [Abstract] [Full Text] [PDF]
|
|